THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnozą raka wątroby
- •Rak można całkowicie usunąć operacyjnie
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Funkcja wątroby klasy Child Pugh A
- •Wystarczająca funkcja nerek, wątroby i szpiku kostnego
- •Nigdy nie otrzymywał podobnych leków immunoterapeutycznych
- •Kobieta w wieku rozrodczym lub mężczyzna zgodzą się na antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Texas Southwestern Medical Center
Dallas, United States
Trial contact
Carrie Manwaring
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.